Northern Trust Company of Connecticut’s Acadia Pharmaceuticals ACAD Stock Holding History

Northern Trust Company of Connecticut’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	$651K	Sell	26,041 -67,415	-72%	-$1.59M	﹤0.01%	1491
2013 Q3	$2.57M	Sell	93,456 -3,060	-3%	-$64K	0.02%	963
2013 Q2	$1.75M	Buy	+96,516	New	+$1.33M	0.01%	1089

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Company of Connecticut's ACAD Position: Q4 2013 in Review

Northern Trust Company of Connecticut reduced its Acadia Pharmaceuticals (ACAD) stake by 72% in Q4 2013, selling an estimated $1.59M and leaving 26,041 shares worth $651K. The position accounts for ﹤0.01% of the portfolio, ranked #1491.

Northern Trust Company of Connecticut first reported a position in ACAD in Q2 2013 and has held it in 3 quarters since. The position peaked at $2.57M in Q3 2013. 155 funds tracked by Wall St. Rank hold ACAD as of Q4 2013.

Northern Trust Company of Connecticut held 26,041 shares of Acadia Pharmaceuticals worth $651K as of Q4 2013.
Northern Trust Company of Connecticut sold 67,415 Acadia Pharmaceuticals shares in Q4 2013, an estimated $1.59M.
Acadia Pharmaceuticals made up ﹤0.01% of Northern Trust Company of Connecticut's portfolio in Q4 2013, its #1491 holding.
Northern Trust Company of Connecticut first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 3 quarters since.
Northern Trust Company of Connecticut's Acadia Pharmaceuticals position peaked at $2.57M in Q3 2013.
155 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2013.

Based on Northern Trust Company of Connecticut's 13F filing for Q4 2013, filed 12 Feb 2014.